SCHEMBL721493

SCHEMBL721493

Cc1c(C(O)C2CCCCC2)oc2cccc(F)c12

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.34
NPC1 O15118 3/20 0.34
IDO1 P14902 3/20 0.34
TDO2 P48775 2/20 0.34
BRD4 O60885 1/20 0.33
EPHX1 P07099 1/20 0.33
DHODH Q02127 1/20 0.33
CYP3A4 P08684 1/20 0.32
CYP2D6 P10635 1/20 0.32
CYP2B6 P20813 1/20 0.32
KCNH2 Q12809 1/20 0.32
ALDH1A1 P00352 2/20 0.32
HTT P42858 2/20 0.32
LMNA P02545 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
CYP2C19 P33261 1/20 0.32
MEN1 O00255 2/20 0.31
KMT2A Q03164 2/20 0.31
RPS6KA2 Q15349 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL720515 0.79 NPC1 (0.51) RAB9ANPC1CYP2D6ALDH1A1HTT
SCHEMBL718925 0.75 NPC1 (0.55) RAB9ANPC1IDO1TDO2BRD4
SCHEMBL721039 0.75 NPC1 (0.44) RAB9ANPC1IDO1TDO2BRD4
SCHEMBL720359 0.74 KDM4E (0.34)
SCHEMBL718548 0.73 RAB9A (0.53) RAB9ANPC1CYP3A4ALDH1A1HTT
SCHEMBL717053 0.72 NPC1 (0.45) RAB9ANPC1IDO1TDO2BRD4
SCHEMBL720757 0.70 CYP2C19 (0.48) RAB9ANPC1ALDH1A1HTTNPSR1
SCHEMBL718063 0.70 RAB9A (0.57) RAB9ANPC1ALDH1A1SMN1; SMN2MEN1
SCHEMBL718862 0.69 NPC1 (0.36) RAB9ANPC1BRD4
SCHEMBL721192 0.69 MCL1 (0.45) RAB9ANPC1BRD4KCNH2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436043-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-07 US disclosed
US-20120270865-A2 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-25 US disclosed
US-20120053173-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-01 US disclosed
EP-2251326-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-11-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053173-A1 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP RAB9A 2454/4885NPC1 902/4885IDO1 2682/4885
US-20120270865-A2 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP RAB9A 2454/4885NPC1 902/4885IDO1 2682/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.